Direct oral anticoagulants (DOACs) have become entrenched as the dominant anticoagulant over the last decade for patients with venous thrombosis and atrial fibrillation.1 Compared to warfarin, bleeding risk is similar or lower for patients on DOACs but clinically relevant bleeding is still a risk, especially for patients with impaired...

The past decade has seen extraordinary and rapid progress in the field of artificial intelligence (AI), which produces computer systems capable of performing tasks that typically require human intelligence. These advancements have yielded wide-ranging applications across various domains that are revolutionising industries and transforming the way humans live and...

Direct oral anticoagulants (DOACs) are widely prescribed for the prevention and treatment of stroke, systemic embolism and venous thromboembolism.1 Their mechanism of action involves direct binding to and inhibition of activated coagulation factors—factor Xa and thrombin—thereby preventing excessive blood clotting.2 Overall, DOACs have favourable efficacy and safety profiles but...

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy.1 The phenotypic expression of HCM is highly diversified with varying extents of myocardial hypertrophy, which can affect different parts of the heart and result in varying extents of left ventricular outflow tract (LVOT) obstruction, diastolic dysfunction and arrhythmic potential. The large...

Rhabdomyolysis is a clinical and biochemical syndrome caused by the breakdown of myocytes and release of intracellular components into the bloodstream.1 A subset of rhabdomyolysis is exertional rhabdomyolysis (ER), which is caused by strenuous physical activity. Risk factors for ER include lack of physical endurance, increased duration and intensity...